ArticleBiophotonics discovery2025
Deployment of a real-time prostate cancer confirmation system with Raman spectroscopy: fine-tuning versus test-time adaptation of 1D CNNs.
Article in Biophotonics discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Raman spectroscopic signatures of prostate cancer progression: correlation with gleason score.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Prostate cancer (PCa) confirmation during needle-based procedures is limited by the lack of intraoperative diagnostic tools. Raman spectroscopy (RS), combined with classification models, offers a promising solution for real-time tissue characterization, potentially improving sampling accuracy and therapy guidance. However, such models require tissue- and organ-specific data, making deployment in studies challenging due to limited data availability. Aim: The aim is to develop a one-dimensional convolutional neural network (1D-CNN) for real-time PCa detection using RS on prospectively collected Approach: A ResNet-based 1D-CNN was trained for binary cancer/normal tissue classification. We implemented a pre-training strategy using retrospective RS data from brain, breast, and prostate (202 patients), along with pre-trained bacterial models, followed by efficient fine-tuning and test-time adaptation (TTA) to adapt to unseen domains. Results: Prospective RS data were acquired using a robotic system from 10 PCa patients (two to five biopsies each). The fine-tuned model achieved 0.76 area under the receiver operating characteristic curve, 0.79 accuracy, 0.83 sensitivity, and 0.72 specificity, outperforming support vector machines. TTA improved predictions when labels were unavailable. Conclusions: Pre-trained 1D-CNNs combined with efficient fine-tuning or TTA enable accurate PCa detection in small-cohort settings using real-time RS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.